Modalis Therapeutics Corporation — Investor Relations & Filings
Modalis Therapeutics Corporation is a biotechnology company developing precision genetic medicines for serious disorders. The company's core technology is CRISPR-GNDM®, a proprietary epigenome editing platform. This technology regulates the expression of specific genes—selectively activating or suppressing them—without altering the underlying DNA sequence or causing double-strand breaks. CRISPR-GNDM® utilizes a compact epigenome editor designed for efficient delivery to target cells using adeno-associated virus (AAV) vectors. The company advances its programs through a hybrid model of in-house development and collaborative partnerships, with a pipeline focused on therapeutic areas such as muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 資金調達に関する補足説明資料 | 2026-05-27 | Japanese | |
| 第三者割当による第19回新株予約権（行使価額修正条項付）及び第２回無担保社債（私募債）の発行並びに新株予約権の買取契約の締結に関するお知らせ | 2026-05-27 | Japanese | |
| 連結子会社における固定資産の譲渡及び特別利益の計上に関するお知らせ | 2026-04-27 | Japanese | |
| 第三者割当により発行された第17回新株予約権（行使価額修正条項付）の行使の完了及び月間行使状況に関するお知らせ | 2026-04-23 | Japanese | |
| ストック・オプション（新株予約権）の発行内容確定に関するお知らせ | 2026-04-14 | Japanese | |
| 第三者割当により発行された第17回新株予約権（行使価額修正条項付）の大量行使に関するお知らせ | 2026-04-14 | Japanese |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 47275834 | 資金調達に関する補足説明資料 | 2026-05-27 | Japanese | ||
| 47275823 | 第三者割当による第19回新株予約権（行使価額修正条項付）及び第２回無担保社債（私募債）の発行並びに新株予約権の買取契約の締結に関するお知らせ | 2026-05-27 | Japanese | ||
| 46879231 | 連結子会社における固定資産の譲渡及び特別利益の計上に関するお知らせ | 2026-04-27 | Japanese | ||
| 46878443 | 第三者割当により発行された第17回新株予約権（行使価額修正条項付）の行使の完了及び月間行使状況に関するお知らせ | 2026-04-23 | Japanese | ||
| 46876892 | ストック・オプション（新株予約権）の発行内容確定に関するお知らせ | 2026-04-14 | Japanese | ||
| 46876891 | 第三者割当により発行された第17回新株予約権（行使価額修正条項付）の大量行使に関するお知らせ | 2026-04-14 | Japanese | ||
| 33037084 | 確認書 | 2026-03-25 | Japanese | ||
| 33037074 | 有価証券報告書－第10期(2025/01/01－2025/12/31) | 2026-03-25 | Japanese | ||
|
2025
7 filings
| |||||
| 7857634 | 訂正有価証券届出書（組込方式） | 2025-08-14 | Japanese | ||
| 7857556 | 確認書 | 2025-08-14 | Japanese | ||
| 7857538 | 半期報告書－第10期(2025/01/01－2025/12/31) | 2025-08-14 | Japanese | ||
| 7859158 | 有価証券届出書（組込方式） | 2025-08-07 | Japanese | ||
| 7270877 | 臨時報告書 | 2025-03-28 | Japanese | ||
| 7272021 | 内部統制報告書－第9期(2024/01/01－2024/12/31) | 2025-03-27 | Japanese | ||
| 7272014 | 確認書 | 2025-03-27 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
89bio, Inc.
Clinical-stage biopharma developing therapies for liver and…
|
ETNB | US | Manufacturing |
|
Aardvark Therapeutics, Inc.
Clinical-stage biopharma developing therapeutics for hunger…
|
AARD | US | Manufacturing |
|
Aarey Drugs & Pharmaceuticals Ltd
Manufactures APIs and chemical intermediates for global pha…
|
AAREYDRUGS | IN | Manufacturing |
|
Aarti Drugs Limited
Produces APIs, pharma intermediates, and specialty chemical…
|
AARTIDRUGS | IN | Manufacturing |
|
Aarti Pharmalabs Limited
Manufacturer of APIs, intermediates, and xanthines with glo…
|
AARTIPHARM | IN | Manufacturing |
|
AAYUSH WELLNESS LIMITED
Develops and markets herbal formulations, supplements, and …
|
539528 | IN | Manufacturing |
|
Ab&B Bio-Tech CO., LTD. JS
Biopharmaceutical company engaged in the R&D and commercial…
|
2627 | HK | Manufacturing |
|
Abbisko Cayman Limited
Clinical-stage biopharma focused on discovering and develop…
|
2256 | KY | Manufacturing |
|
Abbott India Ltd.
Provides pharmaceutical solutions in gastroenterology, card…
|
ABBOTINDIA | IN | Manufacturing |
|
ABBOTT LABORATORIES
Global healthcare company in medical devices, diagnostics, …
|
ABT | US | Manufacturing |
Modalis Therapeutics Corporation via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/14289/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=14289 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=14289 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=14289 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 14289}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Modalis Therapeutics Corporation (id: 14289)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.